Yesterday, Crown Laboratories, Inc. ("Crown"), a Hildred Capital portfolio company and privately held, global innovative leader in the skincare industry, announced the closing of its acquisition of Revance Therapeutics, Inc. ("Revance") (NASDAQ:RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250207314086/en/ Jeff Bedard, Founder and Chief Executive Officer of Crown commented, "We are excited to officially welcome Revance to the Crown family. This acquisition strengthens our leadership position and en

The business combination reinforces Crown's position as a leading, innovative, high-growth aesthetics and skincare company JOHNSON CITY, Tenn., Feb. 6, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced the successful closing of its acquisition of Revance Therapeutics, Inc. ("Revance") (NASDAQ:RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings. The Offer and the Merger Crown's tender offer to acquire all of

JOHNSON CITY, Tenn. and NASHVILLE, Tenn., Feb. 5, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ:RVNC) ("Revance"), today announced that the tender offer to purchase all of the issued and outstanding shares of common stock, par value $0.001 per share ("Shares") of Revance at a purchase price of $3.65 per Share, net to the stockholder in cash without interest and less any required tax withholding (the "Offer"), expired as scheduled at one minute past 11:59 p.m., Eastern Time, on February 4, 2025 and was not extended (such date and time, the "Expiration Time").

Crown offer of $3.65 per share is the only offer available to Revance stockholdersCrown offer unanimously approved by the Revance Board of DirectorsTeoxane withdraws its previous proposal, says it will tender its 6.2% stake in Revance into Crown tender Tender offer expires at one minute past 11:59 p.m., Eastern Time, on February 4, 2025JOHNSON CITY, Tenn. and NASHVILLE, Tenn., Jan. 31, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ:RVNC) ("Revance"), today reminded Revance stockholders of the recommendation to tender their shares in support of Crown's cash tender offer (the "tender offer") to acquire all of the issued and outstanding shares of

Increased offer price to $3.65 per share, a $0.55 per share increase Improved offer unanimously approved by Revance Board of Directors Crown to extend tender offer until 11:59 p.m., Eastern Time, on February 4, 2025 Crown's offer is the only fully-financed offer currently available to Revance's stockholders Outside termination date under the A&R Merger Agreement is February 7, 2025 Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ:RVNC) ("Revance"), today announced that, on January 17, 2025, they amended their previously announced Amended and Restated Merger Agreement (the "Second Amendment," together with the Amended and Restated Merger Agreement, da

JOHNSON CITY, Tenn., Jan. 13, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that, at the request of Revance Therapeutics, Inc., ("Revance") (NASDAQ:RVNC), it has extended the expiration of its cash tender offer to acquire all of the issued and outstanding shares of common stock, par value $0.001 per share ("Shares") of Revance, at a price of $3.10 per Share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire o

Compelling Cash Proposal Provides 16% Premium Over Revance's Amended and Restated Agreement with Crown Laboratories GENEVA, Jan. 6, 2025 /PRNewswire/ -- Teoxane SA today announced that on January 6, 2025, it submitted a proposal to the Board of Directors of Revance Therapeutics, Inc. (NASDAQ:RVNC) to acquire Revance for $3.60 per share in cash. Teoxane beneficially owns 6.2% of the outstanding shares of common stock of Revance. Teoxane's proposal provides a 16% premium over the $3.10 per share price in Revance's amended and restated merger agreement with Crown Laboratories, Inc. ("Crown"), as announced on December 9, 2024. Teoxane believes its proposal is a superior alternative to the amend

Board of Directors of Revance Recommend Stockholders Tender their Shares JOHNSON CITY, Tenn., Dec. 12, 2024 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that it has commenced a cash tender offer to acquire all outstanding shares of common stock of Revance Therapeutics, Inc., ("Revance") (NASDAQ:RVNC) at a price of $3.10 per share in cash. The tender offer is being made in connection with the Amended and Restated Merger Agreement, dated December 7, 2024 (as amended or supplemented from time to time, the "A&R Merger Agreement").

Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, Inc. ("Revance") (NASDAQ:RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings, today announced that they have amended and restated the merger agreement entered into by the parties on August 11, 2024, pursuant to which the companies will seek to merge the two organizations. Under the terms of the amended and restated merger agreement, which has been unanimously approved by Revance's Board of Directors, Crown will commence a tender offer to acquire all outstanding shares of Revance's com

Combination provides opportunity to create a leading, innovative, high-growth aesthetics and skincare company Brings together two high-quality, complementary product lines Combined company's flagship brands to include DAXXIFY® (toxin), the RHA® Collection (filler), SkinPen® (microneedling), PanOxyl® (acne), Blue Lizard® (sunscreen), and StriVectin® (anti-aging) Opportunity for global commercialization capabilities with coverage of >10,000 medical professionals, mass retailers, specialty retailers, club retailers, and an ecommerce channel New product flow potential through internal product development and an integrated manufacturing operation Experienced leadership team that leverages the st

EDMONTON, AB, Nov. 17, 2022 /PRNewswire/ - Nanostics Inc., a precision health diagnostics company, announced today the appointment of Aubrey Rankin to its Board of Directors. Mr. Rankin will join the board of directors at Nanostics replacing Mr. Reg Joseph as one of the independent directors for the company. "We're excited to announce Aubrey Rankin's appointment to Nanostics' Board of Directors. Aubrey's vast experience and insights with patient-provider subscription platforms will be invaluable as we launch our lead prostate cancer diagnostic test, ClarityDX Prostate®," said

- Q1 revenue for the RHA® Collection of dermal fillers of $11.6 million - HintMD's processing volume run-rate more than doubled to over $400 million from the prior quarter - Over 1,500 aesthetic accounts activated across products and services at quarter-end - Status of the U.S. Food and Drug Administration (FDA) pre-approval inspection - Conference call and webcast today at 4:30 p.m. ET Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. Financial Highlights Revenue for the first quarter 2021 totaled $

SAN DIEGO--(BUSINESS WIRE)--​Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update. Financial Highlights Revenue for the fourth quarter and full year ended December 31, 2020 was $11.1 million and $15.3 million compared to $0.1 million and $0.4 million for the same periods in 2019, respectively. The increase was primarily due to the commercial launch of the RHA® Collection of dermal fillers and the HintMD fintech platform. Revenue for the fourth quarter included $10.0 million of

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the appointment of accomplished biotech and pharmaceutical executive, Olivia C. Ware, and fintech and payments thought leader and entrepreneur, Carey O’Connor Kolaja, to its Board of Directors. The appointments will be made effective on March 1, 2021 for Ms. Kolaja and March 6, 2021, for Ms. Ware. “As we continue to grow and evolve our company strategy, it is critical that we expand the focus and expertise of our board. Olivia’s extensive background in drug portfolio and program management and Carey’s deep